Acrodermatitis continua Hallopeau successfully treated by risankizumab
Language English Country Great Britain, England Media print-electronic
Document type Letter
Grant support
Charles University, Prague, Czech Republic.
PubMed
33368238
DOI
10.1111/ijd.15391
Knihovny.cz E-resources
- MeSH
- Acrodermatitis * drug therapy MeSH
- Humans MeSH
- Antibodies, Monoclonal therapeutic use MeSH
- Psoriasis * drug therapy MeSH
- Skin Diseases, Vesiculobullous * MeSH
- Check Tag
- Humans MeSH
- Publication type
- Letter MeSH
- Names of Substances
- Antibodies, Monoclonal MeSH
- risankizumab MeSH Browser
See more in PubMed
Passante M, Dastoli S, Nisticò SP, et al. Effectiveness of brodalumab in acrodermatitis continua of Hallopeau: a case report. Dermatol Ther 2020; 33: e13170.
Di Costanzo L, Napolitano M, Patruno C, et al. Acrodermatitis continua of Hallopeau (ACH): two cases successfully treated with adalimumab. J Dermatolog Treat 2014; 25: 489-494.
Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011; 365: 620-628.
Smith MP, Ly K, Thibodeaux Q, et al. Acrodermatitis continua of Hallopeau: clinical perspectives. Psoriasis (Auckl) 2019; 9: 65-72.
Husson B, Barbe C, Hegazy S, et al. Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau. J Eur Acad Dermatol Venereol 2020; 34: 2330-2338. https://doi.org/10.1111/JDV.16265
